Drug intelligence / Profile preview

artesunate + amodiaquine + primaquine

Development stage: Unknown
Lead developer: Sanofi
Modality: Drug Delivery Systems
Administration: Oral

Overview

This is a triple combination antimalarial therapy consisting of artesunate and amodiaquine (which together form an artemisinin-based combination therapy or ACT) plus primaquine. The combination is used primarily for treating uncomplicated Plasmodium falciparum malaria, with primaquine specifically added to reduce gametocyte carriage and block transmission to mosquitoes.

Targets

Heme

Beyond the preview

Go deeper on artesunate + amodiaquine + primaquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on artesunate + amodiaquine + primaquine.

Explore the full profile